BIVN Bioenvision (MM)

Bioenvision, Inc. (NasdaqGM:BIVN) today announced MaryJane Rafii, Ph.D. has joined the Company as Vice President, Regulatory Affairs effective October 30th. Dr. Rafii brings to Bioenvision over 12 years of pharmaceutical and biotechnology industry experience. The appointment signals the Company�s focus on expanding the markets for its approved products and developing the product pipeline. Dr. Rafii was most recently the head of regulatory affairs at the Ludwig Institute for Cancer Research in Manhattan where she had been since 1999. Dr. Rafii also oversaw regulatory affairs at Sankyo USA in New York from 1995 to 1999. She began her regulatory career at Escalon Ophthalmics in 1993. �Dr. Rafii has the background to design regulatory strategies appropriate for each of the products in our pipeline and to manage certain of our clinical programs we have designed or hope to design for our approved products. We are delighted to have added MaryJane to our team,� said David P. Luci, Chief Financial Officer and General Counsel of Bioenvision. �Dr. Rafii�s background in oncology will be instrumental in expanding the franchise for our leukemia drug Evoltra� (clofarabine),� said Dr. Christopher B. Wood, Chairman and Chief Executive Officer of Bioenvision. �This drug has shown an indication of activity for treating several types of cancer and on a global basis could reach blockbuster status. Dr. Rafii will help the Company maximize the potential for this innovative new therapy.� MaryJane Rafii earned her Ph.D. in immunology and biochemistry from the University of Cardiff, Wales, United Kingdom. She received her master�s degree in protein modeling from UC San Francisco and a bachelor�s degree in molecular biology/marketing and international finance from the University of Southern California. About Bioenvision Bioenvision's primary focus is the acquisition, development, distribution and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Evoltra�, Modrenal� (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products. Bioenvision is also developing anti-infective technologies, including the OLIGON� technology, an advanced biomaterial that has been incorporated into various FDA approved medical devices and Suvus�, an antimicrobial agent currently in clinical development for refractory chronic hepatitis C infection. For more information on Bioenvision please visit our Web site at www.bioenvision.com. Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Bioenvision's compounds under development in particular; the potential failure of Bioenvision's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioenvision's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioenvision's business, structure or projections; the development of competing products; uncertainties related to Bioenvision's dependence on third parties and partners; and those risks described in Bioenvision's filings with the SEC. Bioenvision disclaims any obligation to update these forward-looking statements. Bioenvision, Inc. (NasdaqGM:BIVN) today announced MaryJane Rafii, Ph.D. has joined the Company as Vice President, Regulatory Affairs effective October 30th. Dr. Rafii brings to Bioenvision over 12 years of pharmaceutical and biotechnology industry experience. The appointment signals the Company's focus on expanding the markets for its approved products and developing the product pipeline. Dr. Rafii was most recently the head of regulatory affairs at the Ludwig Institute for Cancer Research in Manhattan where she had been since 1999. Dr. Rafii also oversaw regulatory affairs at Sankyo USA in New York from 1995 to 1999. She began her regulatory career at Escalon Ophthalmics in 1993. "Dr. Rafii has the background to design regulatory strategies appropriate for each of the products in our pipeline and to manage certain of our clinical programs we have designed or hope to design for our approved products. We are delighted to have added MaryJane to our team," said David P. Luci, Chief Financial Officer and General Counsel of Bioenvision. "Dr. Rafii's background in oncology will be instrumental in expanding the franchise for our leukemia drug Evoltra(R) (clofarabine)," said Dr. Christopher B. Wood, Chairman and Chief Executive Officer of Bioenvision. "This drug has shown an indication of activity for treating several types of cancer and on a global basis could reach blockbuster status. Dr. Rafii will help the Company maximize the potential for this innovative new therapy." MaryJane Rafii earned her Ph.D. in immunology and biochemistry from the University of Cardiff, Wales, United Kingdom. She received her master's degree in protein modeling from UC San Francisco and a bachelor's degree in molecular biology/marketing and international finance from the University of Southern California. About Bioenvision Bioenvision's primary focus is the acquisition, development, distribution and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Evoltra(R), Modrenal(R) (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products. Bioenvision is also developing anti-infective technologies, including the OLIGON(R) technology, an advanced biomaterial that has been incorporated into various FDA approved medical devices and Suvus(R), an antimicrobial agent currently in clinical development for refractory chronic hepatitis C infection. For more information on Bioenvision please visit our Web site at www.bioenvision.com. Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Bioenvision's compounds under development in particular; the potential failure of Bioenvision's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioenvision's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioenvision's business, structure or projections; the development of competing products; uncertainties related to Bioenvision's dependence on third parties and partners; and those risks described in Bioenvision's filings with the SEC. Bioenvision disclaims any obligation to update these forward-looking statements.